Feb 13, 2023 / 03:30PM GMT
Unidentified Participant -
You're invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. (Operator Instructions)
One last remark, if you would like to follow the presented slides and as well, please feel free to go to roche.com/investors to download the presentation.
At this time, it's my pleasure to introduce you to Bruno Eschli head of Investor Relations. Bruno, the stage is yours.
Bruno Eschli - Roche Holding AG - Head of IR
Thanks, Henrik. And could I have the first slide, please?
So welcome to our first IR call in 2023, focusing on our fast-growing ophthalmology franchise. And let me quickly guide you through today's agenda. We have 3 speakers with us today.
The first one will be Nilesh Mehta, our Global Franchise Head of Ophthalmology, responsible for global product strategy. Nilesh will provide an update on our overall franchise strategy.
Secondly, we have Christopher
Roche Holding AG Virtual Event - Update following Angiogenesis Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot